ADC Name	PEN-221
Synonyms	PEN 221; PEN221    Click to Show/Hide
Organization	Tarveda Therapeutics, Inc.
Drug Status	Phase 1/2
Antibody Name	Undisclosed
Antigen Name	Somatostatin receptor type 2 (SSTR2)					Antigen Info
Payload Name	Mertansine DM1					Payload Info
Payload Target	Microtubule (MT)					Target Info
Linker Name	Disulfide cleavable linker					Linker Info
Conjugate Type	Site-specific conjugation through the Sortase A.

Standard Type	Value	Units	Description	Reference
Maximum Observed Concentration (Cmax)	5.93	uM	PEN-221 plasma concentration profile following intravenous administration to non-tumor bearing mice, 2 mg/kg.	[1]
Area Under the Concentration-Time Curve (AUC)	7.3	uM·h	PEN-221 plasma concentration profile following intravenous administration to non-tumor bearing mice, 2 mg/kg.	[1]

Standard Type	Value	Units	Description	Reference
Volume of Distribution (Vd)	963	mL/kg	PEN-221 plasma concentration profile following intravenous administration to non-tumor bearing mice, 2 mg/kg.	[1]

Standard Type	Value	Units	Description	Reference
Elimination Half-Life (t1/2)	12.2	h	PEN-221 plasma concentration profile following intravenous administration to non-tumor bearing mice, 2 mg/kg.	[1]
Clearance (CL)	2.32	mL/kg/min	PEN-221 plasma concentration profile following intravenous administration to non-tumor bearing mice, 2 mg/kg.	[1]

Ref 1	Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer